The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
Those who voluntarily signed a written personal information agreement to participate in this clinical study.
Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.
Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
Those who are expected to need insulin prescription during the study period
Pregnant women, breast-feeding women
Patients with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
Cohort
Prospective
Not listed
Target blood pressure control rate
Target blood glucose achievement rate
Click on the lead sponsor to view all of their trials.
